Market Overview

Assisted Reproductive Technology (ART) Market Report 2018-2025 - Analysis & Forecast by By Type (IVF, AI-IUI, FER, Others), End Use (Hospitals, Fertility Clinics) & Procedures


Assisted Reproductive Technology (ART) Market Report 2018-2025 - Analysis & Forecast by By Type (IVF, AI-IUI, FER, Others), End Use (Hospitals, Fertility Clinics) & Procedures

PR Newswire

DUBLIN, Sept. 4, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Assisted Reproductive Technology (ART) Market Size, Share & Trends Analysis Report By Type (IVF, AI-IUI, FER, Others), By End Use (Hospitals, Fertility Clinics), By Procedures And Segment Forecasts, 2018 - 2025" report has been added to's offering.

The global assisted reproductive technology (ART) market is expected to reach USD 45 billion by 2025. Childbearing postponement is one of the high impact rendering drivers of the infertility treatment market. The reproductive behavior and pattern of some of the nations such as few European nations have shifted from early to late childbearing pattern.

Increasing marital age, rising tobacco and alcohol consumption, increasing obesity rate are some of the other factors contributing to the market growth. Furthermore, increasing incidence rate of conditions such as poly-cystic ovarian syndrome (PCOS), tubal factors and endometriosis are other drivers of the market.

According to the Society for Assisted Reproductive Technology, 2012 was the year with highest percentage of babies born through IVF treatment. The treatment has become more successful and has gained more acceptance, which is further expected to increase the market size in the coming years.

Further Key Findings from the Report Suggest:

  • Fresh non-donor was the largest ART market procedure segment in 2014. The fact that fresh eggs and sperms increase the number of successful pregnancies is expected to drive segment growth over the forecast period.
  • According to a recent study published in the New England Journal of the researchers from Vietnam and China, frozen embryos are not more effective in comparison to the fresh embryos for all women, specifically those suffering from PCOS.
  • Frozen non-donor is identified as the most lucrative procedure segment of the assisted reproductive technology industry. A new study claims that the fertility treatment with frozen embryos may have more probability of success than those performed with fresh embryos.
  • IVF with ICSI dominated the technology type market segment owing to increase in the chances of successful fertilization, and exceptional technique for treating male infertility. As per the study published in fertility journal Human Reproduction Update 2017, North America, Europe, New Zealand and Australia, men's sperm counts declined by 50-60% over the period between 1973 and 2011. Changing lifestyle and environmental factors are some of the factors responsible for the decline of sperm counts.
  • Frozen embryo replacement (FER) is anticipated to grow at a rapid rate over the forecast period owing to the fact that in the clinics fresh embryos are used first and only good quality and spare embryos are transferred at a later stage. The trend is to transfer single embryos rather than risking by transferring two or more embryos. This is expected to increase the FER segment market in the coming years.
  • Europe dominated the market and is anticipated to maintain its dominance during the forecast period The Asia Pacific region is likely to witness significant growth over the next decade due to improving healthcare infrastructure, increasing awareness and adoption of IVF procedures.
  • Technological advancements is expected to drive the market in the coming years. In 2016, INVO Bioscience, Inc. announced the FDA approval of first intravaginal culture system, INVOcell, wherein women's vagina is used as a natural incubator and the clinical trials have produced pregnancy similar to traditional IVF treatments
  • Some of the key players are California Cryobank, Bloom IVF Centre, Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Ferring Pharmaceuticals, Boston Science Corporation and Hamilton Throne Ltd.

Key Topics Covered:

Chapter 1 Executive Summary
1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Data Analysis

Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis Constant rise in infertility rate Growing awareness and social acceptance of assisted reproductive technologies Increasing number of single women and same-sex couples
3.1.2 Market restraints analysis Changing government regulations
3.2 Penetration & Growth Prospect Mapping
3.3 Assisted Reproductive Technology - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.4 Assisted Reproductive Technology - Industry Analysis - Porter's

Chapter 4 Assisted Reproductive Technology (ART) Market: Procedure Estimates & Trend Analysis
4.1 Assisted Reproductive Technology (ART): Procedure Analysis
4.2 Fresh Donor
4.3 Fresh Nondonor
4.4 Frozen Donor
4.5 Frozen Nondonor
4.6 Embryo/Egg Banking

Chapter 5 Assisted Reproductive Technology (ART) Market: Type Estimates & Trend Analysis
5.1 Assisted Reproductive Technology (ART): Type Analysis
5.2 IVF
5.2.1 IVF market, 2014 - 2025 (USD Million) IVF with ICSI IVF without ICSI
5.3 AI-IUI
5.4 FER
5.5 Others

Chapter 6 Assisted Reproductive Technology (ART) Market: End-use Estimates & Trend Analysis
6.1 Assisted Reproductive Technology (ART): End-use Analysis
6.2 Hospital
6.3 Fertility Clinics

Chapter 7 Assisted Reproductive Technology (ART) Market: Regional Estimates & Trend Analysis

Chapter 8 Competitive Landscape

  • Cosmos Biomedical
  • Microm UK Ltd.
  • Origio
  • IrvineScientific
  • Cryolab Ltd.
  • Parallabs
  • European Sperm Bank
  • Bloom IVF Centre
  • Ovascience
  • Ferring Pharmaceuticals

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content with multimedia:

SOURCE Research and Markets

View Comments and Join the Discussion!